Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:CURR NASDAQ:ELYM NYSEAMERICAN:OSTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.75+0.9%$2.34$1.23▼$3.23$259.54M2.79422,011 shs232,272 shsCURRCurrenc Group$3.93+12.9%$2.73$0.33▼$4.68$298.99M0.17186,830 shs542,710 shsELYMEliem Therapeutics$9.69+8.8%$7.53$2.35▼$11.55$288.30M-0.39486,688 shs819,804 shsOSTXOS Therapies$1.74+0.3%$1.46$1.15▼$2.57$68.59M-1.34635,644 shs261,962 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+0.37%-0.37%+20.35%+56.32%+98.54%CURRCurrenc Group+1.76%+2.36%+20.91%+144.37%+155.15%ELYMEliem Therapeutics+8.75%+2.00%+47.71%+116.78%+662.99%OSTXOS Therapies+7.45%+6.13%+27.21%+30.08%-21.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$2.75+0.9%$2.34$1.23▼$3.23$259.54M2.79422,011 shs232,272 shsCURRCurrenc Group$3.93+12.9%$2.73$0.33▼$4.68$298.99M0.17186,830 shs542,710 shsELYMEliem Therapeutics$9.69+8.8%$7.53$2.35▼$11.55$288.30M-0.39486,688 shs819,804 shsOSTXOS Therapies$1.74+0.3%$1.46$1.15▼$2.57$68.59M-1.34635,644 shs261,962 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+0.37%-0.37%+20.35%+56.32%+98.54%CURRCurrenc Group+1.76%+2.36%+20.91%+144.37%+155.15%ELYMEliem Therapeutics+8.75%+2.00%+47.71%+116.78%+662.99%OSTXOS Therapies+7.45%+6.13%+27.21%+30.08%-21.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 2.75Moderate Buy$5.0082.15% UpsideCURRCurrenc Group 1.50ReduceN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/AOSTXOS Therapies 2.67Moderate Buy$18.50966.28% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, CURR, ELYM, and CGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/20/2026CGENCompugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/7/2026CGENCompugen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.003/27/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/25/2026CGENCompugen Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/9/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$72.76M3.57$0.39 per share7.06$1.09 per share2.52CURRCurrenc Group$37.81M7.91N/AN/A($0.90) per share-4.37ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AOSTXOS TherapiesN/AN/AN/AN/A($0.17) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen$35.34M$0.377.42N/AN/A48.57%55.68%29.68%5/18/2026 (Estimated)CURRCurrenc Group-$18.43M-$0.30N/AN/AN/A-48.74%N/A-18.92%5/26/2026 (Estimated)ELYMEliem Therapeutics-$35.12M-$0.53N/AN/AN/AN/A-47.03%-45.97%N/AOSTXOS Therapies-$28.75M-$0.79N/AN/AN/AN/A-6,489.80%-378.94%N/ALatest OSTX, CURR, ELYM, and CGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CGENCompugen-$0.07N/AN/AN/A$1.57 millionN/A3/31/2026Q4 2025OSTXOS TherapiesN/A-$0.41N/A-$0.41N/AN/A3/2/2026Q4 2025CGENCompugen$0.05$0.60+$0.55$0.60$14.30 million$67.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/ACURRCurrenc GroupN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A6.566.56CURRCurrenc GroupN/A1.151.15ELYMEliem TherapeuticsN/A60.4160.41OSTXOS TherapiesN/A0.030.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%CURRCurrenc Group56.01%ELYMEliem Therapeutics69.76%OSTXOS TherapiesN/AInsider OwnershipCompanyInsider OwnershipCGENCompugen9.50%CURRCurrenc Group43.30%ELYMEliem Therapeutics4.70%OSTXOS Therapies10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7094.55 million85.57 millionOptionableCURRCurrenc Group276.08 million43.14 millionN/AELYMEliem Therapeutics929.75 million28.35 millionNot OptionableOSTXOS TherapiesN/A39.53 million35.46 millionN/AOSTX, CURR, ELYM, and CGEN HeadlinesRecent News About These CompaniesAnalysts Issue Forecasts for OS Therapies Q1 EarningsMay 6 at 7:58 AM | marketbeat.comAnalysts Offer Predictions for OS Therapies FY2030 EarningsMay 5 at 9:23 AM | marketbeat.comOS Therapies Incorporated (OSTX) Gets a Buy from Lake StreetMay 2, 2026 | theglobeandmail.comOS Therapies (NYSEAMERICAN:OSTX) Receives "Buy" Rating from D. Boral CapitalMay 1, 2026 | americanbankingnews.comOS Therapies Gains EMA Rolling Review for OST-HER2April 30, 2026 | tipranks.comOS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected ...April 30, 2026 | finance.yahoo.comD. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)April 30, 2026 | marketbeat.comOS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic OsteosarcomaApril 30, 2026 | newsfilecorp.comNOS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ETApril 27, 2026 | newsfilecorp.comNWhy OS Therapies Incorporated’s (OSTX) Stock Is Up 10.41%April 25, 2026 | aaii.comAOS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria MonocytogenesApril 16, 2026 | newsfilecorp.comNOS Therapies: OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic AdvisorApril 14, 2026 | finanznachrichten.deOS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic AdvisorApril 13, 2026 | newsfilecorp.comNOS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTXApril 11, 2026 | businesswire.comRosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation - OSTXApril 10, 2026 | tmcnet.comRosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTXApril 10, 2026 | businesswire.comOS Therapies IncorporatedApril 10, 2026 | edition.cnn.comOS Therapies: OS Therapies Appoints Craig Eagle, MD as Strategic AdvisorApril 9, 2026 | finanznachrichten.deOS Therapies Appoints Craig Eagle, MD as Strategic AdvisorApril 8, 2026 | newsfilecorp.comNOS Therapies (NYSEAMERICAN:OSTX) Earns "Buy" Rating from D. Boral CapitalApril 8, 2026 | marketbeat.comOS Therapies bolsters funding to advance OST-HER2 programApril 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThis 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 2026Is D-Wave the Latest Threat to Bitcoin?By Nathan Reiff | April 7, 2026The Quiet Infrastructure Play on Small-Bank SurvivalBy Peter Frank | April 21, 2026Fabs Over Figures: The Market Wakes Up to Intel’s Renaissance By Jeffrey Neal Johnson | April 15, 2026Nebius Group Is Trading Near All-Time Highs, Here's How Far It Has ComeBy Ryan Hasson | April 20, 2026OSTX, CURR, ELYM, and CGEN Company DescriptionsCompugen NASDAQ:CGEN$2.74 +0.03 (+0.92%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Currenc Group NASDAQ:CURR$3.93 +0.45 (+12.93%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.Eliem Therapeutics NASDAQ:ELYM$9.69 +0.78 (+8.75%) As of 05/4/2026Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.OS Therapies NYSEAMERICAN:OSTX$1.74 +0.01 (+0.29%) As of 02:12 PM Eastern This is a fair market value price provided by Massive. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage Years in the Making, AMD’s Upside Movement Has Just Begun Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Pinterest Pins a Profit Play To Its Mood Board Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
